Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hunan Province Tumor Hospital

Criteria

Inclusion Criteria:

• Age ≥ 18 years of age on day of signing informed consent

• Histopathology confirmed non-small cell lung cancer

• Asymptomatic brain metastases

• EGFR/ALK ROS1 driver gene mutation negative

• RECIST 1.1 based available assessment of lesions

• ECOG 0-1

• Brain metastases 1-4

• Single lesion ≤4cm

Exclusion Criteria:

• Patients with contraindication of chemotherapy Pregnant or breast feeding women